Cyclo Operating Income vs Interest Expense Analysis

Stocks . USA . 
Stock . Cyclo Therapeutics
CYTH Stock  USD 0.60  0.02  3.23%   
Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Operating Income and its Interest Expense accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Operating Income vs Interest Expense

Operating Income vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Operating Income account and Interest Expense. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Cyclo Therapeutics' Operating Income and Interest Expense is -0.7. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Operating Income and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Cyclo Therapeutics are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Operating Income i.e., Cyclo Therapeutics' Operating Income and Interest Expense go up and down completely randomly.

Correlation Coefficient

-0.7
Relationship DirectionNegative 
Relationship StrengthWeak

Operating Income

Operating Income is the amount of profit realized from Cyclo Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cyclo Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.
Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Issuance Of Capital Stock is increasing as compared to previous years. The Cyclo Therapeutics' current Sales General And Administrative To Revenue is estimated to increase to 5.52, while Selling General Administrative is projected to decrease to under 2.9 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses15.7M16.8M17.6M18.5M
Cost Of Revenue156.1K138.9K3.5M3.7M

Cyclo Therapeutics fundamental ratios Correlations

Total Assets
Short Long Term Debt Total
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Other Current Liab
Short Term Investments
Current Deferred Revenue
Total Assets
0.150.740.85-0.22-0.96-0.710.810.98-0.28-0.350.980.680.64-0.23-0.160.530.790.730.990.4-0.28-0.420.49-0.3-0.52
Short Long Term Debt Total
0.150.41-0.150.610.11-0.390.14-0.030.570.31-0.03-0.320.580.41-0.140.450.370.470.040.76-0.21-0.37-0.54-0.230.3
Total Current Liabilities
0.740.410.29-0.27-0.64-0.950.940.68-0.34-0.480.680.250.94-0.07-0.20.740.950.990.750.79-0.23-0.180.33-0.27-0.6
Total Stockholder Equity
0.85-0.150.29-0.15-0.89-0.30.450.88-0.19-0.190.880.790.18-0.26-0.040.20.40.280.84-0.04-0.23-0.430.5-0.23-0.33
Property Plant And Equipment Net
-0.220.61-0.27-0.150.420.39-0.49-0.350.990.73-0.35-0.35-0.170.030.12-0.35-0.38-0.22-0.360.05-0.12-0.09-0.68-0.120.85
Net Debt
-0.960.11-0.64-0.890.420.63-0.79-0.990.470.46-0.99-0.74-0.50.280.16-0.45-0.71-0.62-0.98-0.220.20.37-0.650.220.63
Retained Earnings
-0.71-0.39-0.95-0.30.390.63-0.91-0.660.460.56-0.66-0.3-0.95-0.170.23-0.9-0.99-0.94-0.74-0.820.240.29-0.350.280.7
Accounts Payable
0.810.140.940.45-0.49-0.79-0.910.8-0.55-0.60.80.440.81-0.13-0.260.70.930.930.850.58-0.24-0.130.59-0.27-0.76
Cash
0.98-0.030.680.88-0.35-0.99-0.660.8-0.4-0.421.00.710.55-0.29-0.170.460.740.670.990.28-0.22-0.390.6-0.23-0.58
Non Current Assets Total
-0.280.57-0.34-0.190.990.470.46-0.55-0.40.8-0.4-0.36-0.240.030.12-0.41-0.45-0.28-0.42-0.03-0.15-0.04-0.68-0.140.86
Non Currrent Assets Other
-0.350.31-0.48-0.190.730.460.56-0.6-0.420.8-0.42-0.25-0.4-0.010.02-0.49-0.55-0.42-0.46-0.28-0.190.03-0.56-0.170.7
Cash And Short Term Investments
0.98-0.030.680.88-0.35-0.99-0.660.81.0-0.4-0.420.710.55-0.29-0.170.460.740.670.990.28-0.22-0.390.6-0.23-0.58
Net Receivables
0.68-0.320.250.79-0.35-0.74-0.30.440.71-0.36-0.250.710.18-0.25-0.070.220.370.230.7-0.14-0.25-0.070.57-0.25-0.46
Common Stock Shares Outstanding
0.640.580.940.18-0.17-0.5-0.950.810.55-0.24-0.40.550.180.1-0.210.810.940.950.640.9-0.18-0.30.1-0.22-0.49
Non Current Liabilities Total
-0.230.41-0.07-0.260.030.28-0.17-0.13-0.290.03-0.01-0.29-0.250.1-0.190.560.11-0.06-0.220.34-0.06-0.35-0.23-0.050.0
Inventory
-0.16-0.14-0.2-0.040.120.160.23-0.26-0.170.120.02-0.17-0.07-0.21-0.19-0.26-0.22-0.27-0.17-0.02-0.430.49-0.08-0.42-0.02
Other Current Assets
0.530.450.740.2-0.35-0.45-0.90.70.46-0.41-0.490.460.220.810.56-0.260.870.730.560.8-0.18-0.410.2-0.2-0.6
Other Stockholder Equity
0.790.370.950.4-0.38-0.71-0.990.930.74-0.45-0.550.740.370.940.11-0.220.870.940.810.79-0.25-0.330.37-0.28-0.7
Total Liab
0.730.470.990.28-0.22-0.62-0.940.930.67-0.28-0.420.670.230.95-0.06-0.270.730.940.730.79-0.23-0.210.29-0.28-0.55
Total Current Assets
0.990.040.750.84-0.36-0.98-0.740.850.99-0.42-0.460.990.70.64-0.22-0.170.560.810.730.38-0.24-0.390.58-0.26-0.63
Short Term Debt
0.40.760.79-0.040.05-0.22-0.820.580.28-0.03-0.280.28-0.140.90.34-0.020.80.790.790.38-0.18-0.29-0.16-0.22-0.28
Intangible Assets
-0.28-0.21-0.23-0.23-0.120.20.24-0.24-0.22-0.15-0.19-0.22-0.25-0.18-0.06-0.43-0.18-0.25-0.23-0.24-0.18-0.33-0.240.990.34
Common Stock
-0.42-0.37-0.18-0.43-0.090.370.29-0.13-0.39-0.040.03-0.39-0.07-0.3-0.350.49-0.41-0.33-0.21-0.39-0.29-0.330.17-0.31-0.08
Other Current Liab
0.49-0.540.330.5-0.68-0.65-0.350.590.6-0.68-0.560.60.570.1-0.23-0.080.20.370.290.58-0.16-0.240.17-0.24-0.73
Short Term Investments
-0.3-0.23-0.27-0.23-0.120.220.28-0.27-0.23-0.14-0.17-0.23-0.25-0.22-0.05-0.42-0.2-0.28-0.28-0.26-0.220.99-0.31-0.240.35
Current Deferred Revenue
-0.520.3-0.6-0.330.850.630.7-0.76-0.580.860.7-0.58-0.46-0.490.0-0.02-0.6-0.7-0.55-0.63-0.280.34-0.08-0.730.35
Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

High Positive Relationship

Cash And Short Term Investments
+ 1.0
Cash
Total Current Assets
+ 0.99
Total Assets
Total Liab
+ 0.99
Total Current Liabilities
Non Current Assets Total
+ 0.99
Property Plant And Equipment Net
Total Current Assets
+ 0.99
Cash
Total Current Assets
+ 0.99
Cash And Short Term Investments

High Negative Relationship

Other Stockholder Equity
- 0.99
Retained Earnings
Cash And Short Term Investments
- 0.99
Net Debt
Cash
- 0.99
Net Debt
Total Current Assets
- 0.98
Net Debt
Net Debt
- 0.96
Total Assets
Common Stock Shares Outstanding
- 0.95
Retained Earnings

Cyclo Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets4.1M14.2M19.5M4.2M13.2M13.9M
Total Current Liabilities3.1M3.7M3.8M3.5M8.5M8.9M
Total Stockholder Equity936.0K10.5M15.7M734.5K4.8M2.6M
Property Plant And Equipment Net64.6K87.9K77.2K56.7K929.3K505.7K
Net Debt(2.7M)(12.7M)(16.4M)(1.5M)(8.2M)(7.8M)
Retained Earnings(25.1M)(34.1M)(48.3M)(63.8M)(83.9M)(79.7M)
Accounts Payable3.1M3.5M3.7M2.2M4.9M5.1M
Cash2.8M12.8M16.6M1.5M9.2M9.7M
Non Current Assets Total155.2K137.7K84.5K56.7K929.3K694.6K
Non Currrent Assets Other90.6K49.8K7.3K(56.7K)38.3K36.4K
Cash And Short Term Investments2.8M12.8M16.6M1.5M9.2M9.7M
Net Receivables182.5K111.8K539.1K55.0K122.4K105.2K
Common Stock Shares Outstanding1.1M1.6M6.4M8.4M16.3M17.1M
Liabilities And Stockholders Equity4.1M14.2M19.5M4.2M13.2M13.9M
Non Current Liabilities Total36.1K62.9K18.0K3.5M22.5K21.4K
Inventory242.6K237.9K227.4K254.5K254.4K250.7K
Other Current Assets749.2K854.4K2.1M4.6M2.7M2.8M
Other Stockholder Equity26.0M44.5M64.0M64.5M88.6M93.0M
Total Liab3.2M3.7M3.8M3.5M8.5M8.9M
Total Current Assets4.0M14.1M19.4M4.2M12.3M12.9M
Common Stock12.2K477.0841.0849.02.9K3.7K
Net Tangible Assets936.0K10.5M15.7M734.5K844.7K802.5K
Other Assets129.7K90.6K49.8K7.3K6.6K6.2K
Property Plant Equipment64.6K87.9K77.2K56.7K65.2K56.7K
Net Invested Capital936.0K10.6M15.8M734.5K4.8M5.5M
Property Plant And Equipment Gross64.6K87.9K159.3K158.2K1.1M1.1M
Net Working Capital816.9K10.4M15.6M677.9K3.9M5.2M
Capital Stock12.2K477.0841.0849.02.9K3.5K

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:
How To Invest In Cyclo
Details
Is Cyclo Stock a good investment?
Details
What is Cyclo Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.046
Quarterly Revenue Growth
0.051
Return On Assets
(2.82)
Return On Equity
(226.64)
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY